DK1355631T3 - Oral, hurtigt smeltende formulering af cyclooxygenase 2 inhibitor - Google Patents

Oral, hurtigt smeltende formulering af cyclooxygenase 2 inhibitor

Info

Publication number
DK1355631T3
DK1355631T3 DK01965984T DK01965984T DK1355631T3 DK 1355631 T3 DK1355631 T3 DK 1355631T3 DK 01965984 T DK01965984 T DK 01965984T DK 01965984 T DK01965984 T DK 01965984T DK 1355631 T3 DK1355631 T3 DK 1355631T3
Authority
DK
Denmark
Prior art keywords
fast
cyclooxygenase
oral
granules
blending
Prior art date
Application number
DK01965984T
Other languages
English (en)
Inventor
Trang T Le
Tugrul T Kararli
Mark J Kontny
Srikonda V Sastry
Janaki R Nyshadham
Arthur J Pagliero Jr
Original Assignee
Astellas Pharma Technologies I
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Technologies I, Pharmacia Corp filed Critical Astellas Pharma Technologies I
Application granted granted Critical
Publication of DK1355631T3 publication Critical patent/DK1355631T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01965984T 2000-08-18 2001-08-17 Oral, hurtigt smeltende formulering af cyclooxygenase 2 inhibitor DK1355631T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22634700P 2000-08-18 2000-08-18
PCT/US2001/025803 WO2002015885A2 (en) 2000-08-18 2001-08-17 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
DK1355631T3 true DK1355631T3 (da) 2008-02-04

Family

ID=22848576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01965984T DK1355631T3 (da) 2000-08-18 2001-08-17 Oral, hurtigt smeltende formulering af cyclooxygenase 2 inhibitor

Country Status (20)

Country Link
US (1) US20020049233A1 (da)
EP (2) EP1355631B1 (da)
JP (2) JP2004506681A (da)
KR (1) KR20030045035A (da)
CN (1) CN1638739A (da)
AT (1) ATE374599T1 (da)
AU (3) AU2001286533A1 (da)
BR (1) BR0113293A (da)
CA (2) CA2420190A1 (da)
CZ (1) CZ2003422A3 (da)
DE (1) DE60130801T2 (da)
DK (1) DK1355631T3 (da)
ES (1) ES2292614T3 (da)
IL (1) IL154386A0 (da)
MX (2) MXPA03001346A (da)
NO (1) NO20030727L (da)
NZ (2) NZ524115A (da)
PL (1) PL360704A1 (da)
PT (1) PT1355631E (da)
WO (2) WO2002015885A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
EA200400352A1 (ru) * 2001-09-26 2004-12-30 Фармация Корпорейшн Органолептически приемлемые распадающиеся во рту композиции
HUP0401776A2 (hu) * 2001-10-10 2004-12-28 Pharmacia Corporation Intraorálisan széteső valdekoxib készítmények porlasztásos szárítási eljárással előállítva
EP1446088A2 (en) * 2001-11-07 2004-08-18 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1809248A2 (en) * 2004-11-04 2007-07-25 Merck & Co., Inc. Process for granulating particles
JP4945917B2 (ja) * 2005-01-19 2012-06-06 大正製薬株式会社 薬物含有コーティング用核粒子
WO2006125141A2 (en) 2005-05-17 2006-11-23 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives
US20070098804A1 (en) * 2005-08-29 2007-05-03 Judith Aronhime Solid particulate tadalafil having a bimodal particle size distribution
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
WO2007071420A1 (en) * 2005-12-23 2007-06-28 Lek Pharmaceuticals D.D. Bursting pellets
EP2222282A1 (en) * 2007-11-15 2010-09-01 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
KR20210062731A (ko) 2012-03-07 2021-05-31 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CN104027319A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 一种塞来昔布分散片及其制备方法
EA038986B1 (ru) 2014-09-30 2021-11-18 Амикус Терапьютикс, Инк. Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов
BR112018013151A2 (pt) 2015-12-30 2018-12-18 Amicus Therapeutics Inc alfa-glicosidase ácida aumentada para o tratamento da doença de pompe
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN108576205B (zh) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 一种草莓联合干燥的处理方法
WO2020106522A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
JP2020183359A (ja) * 2019-05-09 2020-11-12 日医工株式会社 セレコキシブ含有医薬組成物
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL187160B1 (pl) * 1994-01-31 2004-05-31 Yamanouchi Pharma Co Ltd Sposób wytwarzania rozpuszczalnej wewnątrzustnie formowanej tłocznie wypraski
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PE10898A1 (es) * 1995-06-13 1998-03-20 American Home Prod Formulaciones orales de etodolac s (+)-
HUP9902889A3 (en) * 1996-05-17 2002-04-29 Merck Frosst Canada & Co Kirkl The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
IL144763A0 (en) * 1999-12-08 2002-06-30 Pharmacia Corp Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
SK11802003A3 (sk) * 2001-02-27 2004-06-08 Ranbaxy Laboratories Limited Rýchlo rozpustné tablety enzýmového inhibítora cyklooxygenázy-2

Also Published As

Publication number Publication date
ATE374599T1 (de) 2007-10-15
AU8653001A (en) 2002-03-04
MXPA03001346A (es) 2003-06-06
CA2420190A1 (en) 2002-02-28
ES2292614T3 (es) 2008-03-16
DE60130801T2 (de) 2008-06-26
US20020049233A1 (en) 2002-04-25
WO2002015886A3 (en) 2002-07-25
JP2004506681A (ja) 2004-03-04
NO20030727L (no) 2003-03-24
CA2418730A1 (en) 2002-02-28
BR0113293A (pt) 2003-06-10
NO20030727D0 (no) 2003-02-14
AU2001286530B2 (en) 2007-01-25
WO2002015886A2 (en) 2002-02-28
NZ524123A (en) 2005-02-25
KR20030045035A (ko) 2003-06-09
IL154386A0 (en) 2003-09-17
JP2004512274A (ja) 2004-04-22
CN1638739A (zh) 2005-07-13
WO2002015885A3 (en) 2003-08-28
PT1355631E (pt) 2007-11-29
EP1355631B1 (en) 2007-10-03
NZ524115A (en) 2004-10-29
EP1309316A2 (en) 2003-05-14
PL360704A1 (en) 2004-09-20
AU2001286533A1 (en) 2002-03-04
MXPA03001408A (es) 2005-06-30
WO2002015885A2 (en) 2002-02-28
CZ2003422A3 (cs) 2003-06-18
EP1355631A2 (en) 2003-10-29
DE60130801D1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DK1355631T3 (da) Oral, hurtigt smeltende formulering af cyclooxygenase 2 inhibitor
TWI256305B (en) Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same
NO20003196D0 (no) Umiddelbart smeltende doseringsformulering
IS5526A (is) 11ß-Halógen-7alfa-setin estratríen, aðferð til framleiðslu á lyfjasamsetningum sem innihalda fyrrnefnd estratríen og notkun þeirra til framleiðslu á læknislyfjum
DK1150961T3 (da) Pyrazolcarboxylsyrederivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
HUP0400636A3 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
MA26968A1 (fr) Compositions pharmaceutiques contenant du maleate d'amlodipine.
DK1263721T3 (da) Farmaceutiske sammensætninger, der indeholder 3-aminoazetidinderivater, nye derivater og fremstilling deraf
CA2284051A1 (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates
DK1353919T3 (da) Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme
DK199900554A (da) Paroxetinsalte, fremgangsmåde til fremstilling deraf, farmaceutiske præparater omfattende disse og anvendelser deraf
DK200300344U1 (da) Amlodipinmaleat og farmaceutisk præparat indeholdende amlodipinmaleat
IS2806B (is) 5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridínýl á hreinu kristallaformi og aðferð til efnasmíði
DK1210119T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
IL151912A0 (en) Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
DE60103276D1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
AR034435A1 (es) Agentes terapeuticos.
HUP0204422A3 (en) Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them
WO2005037192A3 (en) Ibuprofen narcotic composition and method for making same
WO2004087648A3 (en) Stabilized phenytoin containing composition